Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$34.43M-65.9%$98.05M+5,883%$42.39M+2,116%$88.43M+1,317%$100.97M+1,832%
$98.47M-3.6%$118.81M+4,459%$78.18M-36.2%$91.65M$102.18M
$109.81M+6.5%$121.74M+1,876%$81.18M-33.8%$92.84M$103.09M
$905K-61.9%$1.28M-17.9%$494K+869%$3.68M$2.37M
$8.08M+13.1%$9.71M-60.7%$6.07M+330%$7.65M$7.14M
$41.25M+5.2%$42.92M-24.4%$39.31M+2,684%$39.73M$39.22M
$2K0.0%$2K$2K-81.8%$2K$2K
-$170.86M-34.8%-$160M-37.3%-$150M+78.5%-$138.11M-$126.76M
$68.56M+7.3%$78.81M+182%$41.87M+147%$53.12M+203%$63.87M+234%
$109.81M+6.5%$121.74M+1,876%$81.18M-33.8%$92.84M$103.09M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Kalaris Therapeutics, Inc. Common Stock's total assets?
Kalaris Therapeutics, Inc. Common Stock (KLRS) holds $109.8M in total assets, up 6.5% year over year.
How much debt does Kalaris Therapeutics, Inc. Common Stock have?
Kalaris Therapeutics, Inc. Common Stock carries $1.4M in total debt against $68.6M of shareholders' equity, a debt-to-equity ratio of 0.02.
How much cash does Kalaris Therapeutics, Inc. Common Stock have?
Kalaris Therapeutics, Inc. Common Stock holds $34.4M in cash and equivalents.
Can Kalaris Therapeutics, Inc. Common Stock cover its short-term obligations?
Its current ratio is 12.19 — current assets exceed current liabilities.
Where does Kalaris Therapeutics, Inc. Common Stock's balance sheet data come from?
Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.